Business Wire

Velodyne Lidar Announces Anand Gopalan as New CEO

Share

Velodyne Lidar, Inc. today announced Anand Gopalan as its new CEO. Gopalan, who previously was Velodyne’s CTO, assumes the position from Velodyne’s legendary founder David Hall. Hall will continue as full-time Chairman of the Board and remain actively involved in directing the company’s technology, product vision and business strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106006044/en/

Velodyne Lidar, Inc. announced Anand Gopalan as its new Chief Executive Officer (CEO). (Photo: Velod ...

Velodyne Lidar, Inc. announced Anand Gopalan as its new Chief Executive Officer (CEO). (Photo: Velodyne Lidar)

Gopalan is a distinguished engineer and technology executive with experience building and leading worldwide engineering organizations. He came to Velodyne in 2016 to form an advanced research and development team. Gopalan leads Velodyne’s customer-focused technology and product development teams to address market needs for lidar solutions designed for high performance, cost optimization and high-volume production.

Over the past three years, Gopalan has worked closely with Hall to develop the company’s technological roadmap and strategic vision. Gopalan is recognized across the industry as a thought leader in business as well as in technology. Recently, Gopalan became more active as a spokesman for the company, expertly explaining the benefits and the workings of lidar to audiences around the world. It is the policy of Velodyne to promote from within the company and Gopalan was a natural choice, having proved himself in 2019.

Gopalan and the Velodyne team look forward to building on the company’s growth trajectory. Due to the breadth and versatility of the Velodyne lidar portfolio, the company continues to make revolutionary contributions to the ever-expanding autonomous industry. Velodyne is a recognized leader in a wide range of markets including automotive, mapping, on-demand mobility, robotics, security, unmanned aerial vehicles (UAV) and more.

Under Gopalan’s leadership alongside Hall, Velodyne brought to market a series of breakthrough lidar products, including the Alpha Prime™, Velarray™, VelaDome™ and a new game-changing lidar sensor, soon to be used for powerful Advanced Driver Assistance Systems (ADAS). Due to its low cost, this sensor will advance automotive safety for the everyday car owner. At CES 2020, Velodyne will unveil the new lidar sensor and Gopalan will discuss his vision for the company at a press conference in the Velodyne booth #7520 on Tuesday, January 7, at 11:00 a.m. PST.

David Hall invented groundbreaking 3D lidar sensor technology in 2005 which set the stage for revolutionizing the automobile industry and was the foundation for Velodyne’s market leadership. The idea of leveraging lidar technology for autonomous driving came to Hall while participating in the DARPA Grand Challenge for autonomous vehicles. Holding more than 30 U.S. patents, Hall is a technology visionary and serial inventor covering a variety of applications, including lidar, audio and marine. The Intellectual Property Owners Education Foundation presented Hall with its 2018 Inventor of the Year Award.

“Anand Gopalan and I have worked side-by-side on Velodyne’s technology roadmap. He is the right executive to lead Velodyne in its next growth phase,” said Hall. “His finger is on the pulse of customer and market needs while possessing the technical brilliance and leadership skills to innovate and deliver. As Chairman, Anand has my full support while I continue to provide vision, strategize and invent.”

“David Hall is more than the founder of Velodyne, he is also the founder of our industry. I am grateful for the trust he has placed in me and excited to lead a company with such a deep history in innovation as Velodyne. We are the forefront of our market, ready to drive the age of autonomy. Velodyne is bringing improved mobility and safety through versatility, responsiveness and agility,” said Gopalan.

Elevating Gopalan to CEO will enhance the leadership team at Velodyne Lidar, running day-to-day business as the company addresses U.S. and global market opportunities. Gopalan and Hall will continue to be supported by a strong bench of Velodyne executive C-staff, including Marta Hall, Chief Marketing Officer (CMO), Rick Tewell, Chief Operating Officer (COO), Mike Jellen, Chief Commercial Officer (CCO), Drew Hamer, Chief Financial Officer (CFO), Barbara Rogan, General Counsel, and Mircea Gradu, Senior Vice President of Product and Quality.

About Velodyne Lidar

Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.

Contact information

Sean Dowdall
Landis Communications Inc. for Velodyne Lidar, Inc.
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom